Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535043 | PMC |
| http://dx.doi.org/10.1177/2045125315584869 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Agomelatine: The Cinderella of migraine pharmacotherapy in pediatrics?
CNS Spectr
December 2024
Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran.
Efficacy of Melatonin as a Promising Intervention for Migraine Prevention: A Systematic Review of Randomized Control Trials.
Cureus
October 2024
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Article Synopsis
- The use of melatonin as an over-the-counter supplement has increased due to more people experiencing sleep-wake disorders, especially during the post-COVID-19 era.
- This systematic review investigates the effectiveness and side effects of melatonin for migraine prevention, comparing it to standard treatments and placebos, based on data from seven high-quality randomized control trials with 1,283 participants.
- Findings suggest that melatonin may significantly reduce migraine frequency and severity, though its specific dosage and additional benefits, such as weight control, need further investigation.
The effectiveness of agomelatine on headache severity and frequency in episodic migraine without aura; a parallel randomized controlled trial study.
BMC Neurol
January 2024
Nursing Education Nursing and Midwifery Care Research Center, School of Nursing & Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Background: Migraine is a headache disorder that affects public health and reduces the patient's quality of life. Preventive medication is necessary to prevent acute attacks and medication overuse headaches (MOH). Agomelatine is a melatonin antagonist.
View Article and Find Full Text PDFCombining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression.
J Psychiatr Res
September 2021
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; Center for Brain Research, Medical University of Vienna, Vienna, Austria. Electronic address:
Despite plenty of effective antidepressant (AD) treatments, the outcome of major depressive disorder (MDD) is often unsatisfactory, probably due to improvable exploitation of available therapies. This European, cross-sectional, naturalistic multicenter study investigated the frequency of additional psychotherapy in terms of a manual-driven psychotherapy (MDP) in 1410 adult in- and outpatients with MDD, who were primarily treated with AD psychopharmacotherapy. Socio-demographic and clinical patterns were compared between patients receiving both treatments and those lacking concomitant MDP.
View Article and Find Full Text PDFSuccessful agomelatine monotherapy for an adolescent with attention deficit hyperactivity disorder and comorbid migraine.
CNS Spectr
April 2022
Almanara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!